Publications and Data Presentations

Activity of EZH2 inhibitors as monotherapy and in combination with multiple myeloma therapies

Apr, 2017

Tazemetostat Phase 1 NHL Update at ASH Lymphoma

Jun, 2016 | ASH Lymphoma Biology

Tazemetostat Early Phase 2 NHL Study Findings Poster at ASH Lymphoma

Jun, 2016 | ASH Lymphoma Biology

Tazemetostat Early Phase 2 NHL Study Findings at ASH Lymphoma

Jun, 2016 | ASH Lymphoma Biology

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor Pinometostat (EPZ-5676) in Children with MLL-r Acute Leukemia: Safety, Exposure and Evidence of Target Inhibition

Dec, 2015

Identification of biomarkers and pathways associated with response to DOT1L inhibitor Pinometostat (EPZ-5676) in MLL-r leukemia

Nov, 2015

Pinometostat, EPZ-5676, Enhances the Anti-Proliferative Activity of MAP Kinase Pathway Inhibitors in Cell Lines Less Sensitive to DOT1L inhibition

Nov, 2015

EZH2 plays a critical role in B-cell maturation and in non-Hodgkin’s lymphoma: Interplay between EZH2 function and B-cell activation

Nov, 2015

CRISPR Pooled Screening Identifies Differential Dependencies on Epigenetic Pathways

Nov, 2015

A Medium-Throughput Single Cell CRISPR/Cas9 Assay to Assess Gene Essentiality

Nov, 2015

Identification of a First-In-Class PRMT5 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Dec, 2014 | ASH

Preclinical Evaluation of EZH2 Inhibitors in Models of Human Synovial Sarcoma

Oct, 2014

Small Molecule Control of Chromatin Remodeling

Sep, 2014 | Chemistry & Biology Review

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells

Jul, 2014 | Journal of Pharmacology and Experimental Therapeutics

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 Mutant Non-Hodgkin Lymphoma

Feb, 2014 | Molecular Cancer Therapeutics

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies in Preclinical Models

Dec, 2013 | ASH

Potent inhibition of DOT1L as a treatment for MLL-fusion leukemia

Aug, 2013 | Blood

Epizyme® announces that the “Nature Reprint Collection: Epigenetics” from Nature Publishing Group is now available online

May, 2013 | Nature Reprint Collection

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Mar, 2013 | PNAS

Chemogenetic analysis of human protein methyltransferases

Jun, 2011 | Chemical Biology & Drug Design

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

Oct, 2010 | PNAS

Epizyme Scientific Publications Reference

Jan, 2008